Global (United States, European Union and China) Encephalitis Vaccine

Encephalitis Vaccine Comprehensive Study by Application (Child, Adult), End User (Hospitals, Clinics, Vaccination Centers, Others), Strain (Nakayama, Beijing, P-3, SA 14-14-2) Players and Region - Global Market Outlook to 2030

Encephalitis Vaccine Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Encephalitis Vaccine
Encephalitis virus is a mosquito-borne Flavivirus that can be transmitted from mosquitoes to wading birds, pigs, and other vertebrate hosts. This virus can be prevented using Encephalitis vaccines.The incidence rate for the Encephalitis virus is in a general low but can depend on the location and the season. This virus can be prevented using Encephalitis vaccines.The rise in government initiatives and recommendations to immunize children is also aiding the growth of the market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Analyst at AMA Research estimates that Chinese Players will contribute the maximum growth to Global Encephalitis Vaccine market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Liaoning Chengda (China), Wuhan Institute of Biological (China), Valneva (France), Tiantan Biological Products (China), Sanofi Pasteur (France), Chengdu Institute of Biological Products (China), GlaxoSmithKline (United Kingdom), Lanzhou Institute of Biological Products (China), Zhejiang Tianyuan Bio-Pharmaceutical (China) and Biken (Japan) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Encephalitis Vaccine market by , Application (Child and Adult) and Region.



On the basis of geography, the market of Encephalitis Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospitals will boost the Encephalitis Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Strain, the sub-segment i.e. Nakayama will boost the Encephalitis Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Research and Development Activities

Market Growth Drivers:
High Mortality and Morbidity Rate caused due to the Incidence of Encephalitis Virus and Rise in Government Initiatives and Recommendations to Immunize Children

Challenges:
Stringent Government Rules and Regulations for Vaccine Approval

Restraints:
Side Effects of the Varicella Live Vaccine

Opportunities:
Growth in the Healthcare Sector Worldwide and Growing Number of Campaigns and Programs for the Improvement in Awareness regarding the Benefits of Vaccines

Market Leaders and their expansionary development strategies
In September 2022, NSW expanded free access to the Japanese encephalitis (JE) vaccine to residents living in affected regional areas to protect those most at risk.
In Sept 2020, Valneva SE announced the signing of a new contract, lasting up to three years, with the U.S. government Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine IXIARO®., and In Oct 2019, Bavarian Nordic A/S announced the initiation of the first-in-human trial of MVA-BN® WEV, a prophylactic vaccine candidate against the equine encephalitis virus - a rare, but potentially deadly illness.


Key Target Audience
Encephalitis Vaccine Manufacturers, Encephalitis Vaccine Traders/Distributors, Encephalitis Vaccine Importer/Exporter, Regulatory & Government Bodies, Research & Consulting Firms, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Child
  • Adult
By End User
  • Hospitals
  • Clinics
  • Vaccination Centers
  • Others

By Strain
  • Nakayama
  • Beijing
  • P-3
  • SA 14-14-2

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Mortality and Morbidity Rate caused due to the Incidence of Encephalitis Virus
      • 3.2.2. Rise in Government Initiatives and Recommendations to Immunize Children
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations for Vaccine Approval
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Encephalitis Vaccine, by Application, End User, Strain and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Encephalitis Vaccine (Value)
      • 5.2.1. Global Encephalitis Vaccine by: Application (Value)
        • 5.2.1.1. Child
        • 5.2.1.2. Adult
      • 5.2.2. Global Encephalitis Vaccine by: End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Vaccination Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Encephalitis Vaccine by: Strain (Value)
        • 5.2.3.1. Nakayama
        • 5.2.3.2. Beijing
        • 5.2.3.3. P-3
        • 5.2.3.4. SA 14-14-2
      • 5.2.4. Global Encephalitis Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Encephalitis Vaccine (Price)
  • 6. Encephalitis Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Liaoning Chengda (China)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Wuhan Institute of Biological (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Valneva (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Tiantan Biological Products (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi Pasteur (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Chengdu Institute of Biological Products (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lanzhou Institute of Biological Products (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Zhejiang Tianyuan Bio-Pharmaceutical (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biken (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Encephalitis Vaccine Sale, by Application, End User, Strain and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Encephalitis Vaccine (Value)
      • 7.2.1. Global Encephalitis Vaccine by: Application (Value)
        • 7.2.1.1. Child
        • 7.2.1.2. Adult
      • 7.2.2. Global Encephalitis Vaccine by: End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Vaccination Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Encephalitis Vaccine by: Strain (Value)
        • 7.2.3.1. Nakayama
        • 7.2.3.2. Beijing
        • 7.2.3.3. P-3
        • 7.2.3.4. SA 14-14-2
      • 7.2.4. Global Encephalitis Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Encephalitis Vaccine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Encephalitis Vaccine: by Application(USD Million)
  • Table 2. Encephalitis Vaccine Child , by Region USD Million (2018-2023)
  • Table 3. Encephalitis Vaccine Adult , by Region USD Million (2018-2023)
  • Table 4. Encephalitis Vaccine: by End User(USD Million)
  • Table 5. Encephalitis Vaccine Hospitals , by Region USD Million (2018-2023)
  • Table 6. Encephalitis Vaccine Clinics , by Region USD Million (2018-2023)
  • Table 7. Encephalitis Vaccine Vaccination Centers , by Region USD Million (2018-2023)
  • Table 8. Encephalitis Vaccine Others , by Region USD Million (2018-2023)
  • Table 9. Encephalitis Vaccine: by Strain(USD Million)
  • Table 10. Encephalitis Vaccine Nakayama , by Region USD Million (2018-2023)
  • Table 11. Encephalitis Vaccine Beijing , by Region USD Million (2018-2023)
  • Table 12. Encephalitis Vaccine P-3 , by Region USD Million (2018-2023)
  • Table 13. Encephalitis Vaccine SA 14-14-2 , by Region USD Million (2018-2023)
  • Table 14. South America Encephalitis Vaccine, by Country USD Million (2018-2023)
  • Table 15. South America Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 16. South America Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 17. South America Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 18. Brazil Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 19. Brazil Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 20. Brazil Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 21. Argentina Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 22. Argentina Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 23. Argentina Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 24. Rest of South America Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 25. Rest of South America Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 26. Rest of South America Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 27. Asia Pacific Encephalitis Vaccine, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 29. Asia Pacific Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 30. Asia Pacific Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 31. China Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 32. China Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 33. China Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 34. Japan Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 35. Japan Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 36. Japan Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 37. India Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 38. India Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 39. India Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 40. South Korea Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 41. South Korea Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 42. South Korea Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 43. Taiwan Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 44. Taiwan Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 45. Taiwan Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 46. Australia Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 47. Australia Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 48. Australia Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 52. Europe Encephalitis Vaccine, by Country USD Million (2018-2023)
  • Table 53. Europe Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 54. Europe Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 55. Europe Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 56. Germany Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 57. Germany Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 58. Germany Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 59. France Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 60. France Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 61. France Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 62. Italy Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 63. Italy Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 64. Italy Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 65. United Kingdom Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 66. United Kingdom Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 67. United Kingdom Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 68. Netherlands Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 69. Netherlands Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 70. Netherlands Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 71. Rest of Europe Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 72. Rest of Europe Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 73. Rest of Europe Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 74. MEA Encephalitis Vaccine, by Country USD Million (2018-2023)
  • Table 75. MEA Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 76. MEA Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 77. MEA Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 78. Middle East Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 79. Middle East Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 80. Middle East Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 81. Africa Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 82. Africa Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 83. Africa Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 84. North America Encephalitis Vaccine, by Country USD Million (2018-2023)
  • Table 85. North America Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 86. North America Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 87. North America Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 88. United States Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 89. United States Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 90. United States Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 91. Canada Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 92. Canada Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 93. Canada Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 94. Mexico Encephalitis Vaccine, by Application USD Million (2018-2023)
  • Table 95. Mexico Encephalitis Vaccine, by End User USD Million (2018-2023)
  • Table 96. Mexico Encephalitis Vaccine, by Strain USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Encephalitis Vaccine: by Application(USD Million)
  • Table 108. Encephalitis Vaccine Child , by Region USD Million (2025-2030)
  • Table 109. Encephalitis Vaccine Adult , by Region USD Million (2025-2030)
  • Table 110. Encephalitis Vaccine: by End User(USD Million)
  • Table 111. Encephalitis Vaccine Hospitals , by Region USD Million (2025-2030)
  • Table 112. Encephalitis Vaccine Clinics , by Region USD Million (2025-2030)
  • Table 113. Encephalitis Vaccine Vaccination Centers , by Region USD Million (2025-2030)
  • Table 114. Encephalitis Vaccine Others , by Region USD Million (2025-2030)
  • Table 115. Encephalitis Vaccine: by Strain(USD Million)
  • Table 116. Encephalitis Vaccine Nakayama , by Region USD Million (2025-2030)
  • Table 117. Encephalitis Vaccine Beijing , by Region USD Million (2025-2030)
  • Table 118. Encephalitis Vaccine P-3 , by Region USD Million (2025-2030)
  • Table 119. Encephalitis Vaccine SA 14-14-2 , by Region USD Million (2025-2030)
  • Table 120. South America Encephalitis Vaccine, by Country USD Million (2025-2030)
  • Table 121. South America Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 122. South America Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 123. South America Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 124. Brazil Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 125. Brazil Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 126. Brazil Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 127. Argentina Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 128. Argentina Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 129. Argentina Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 130. Rest of South America Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 131. Rest of South America Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 132. Rest of South America Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 133. Asia Pacific Encephalitis Vaccine, by Country USD Million (2025-2030)
  • Table 134. Asia Pacific Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 135. Asia Pacific Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 136. Asia Pacific Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 137. China Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 138. China Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 139. China Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 140. Japan Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 141. Japan Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 142. Japan Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 143. India Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 144. India Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 145. India Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 146. South Korea Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 147. South Korea Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 148. South Korea Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 149. Taiwan Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 150. Taiwan Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 151. Taiwan Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 152. Australia Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 153. Australia Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 154. Australia Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 158. Europe Encephalitis Vaccine, by Country USD Million (2025-2030)
  • Table 159. Europe Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 160. Europe Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 161. Europe Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 162. Germany Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 163. Germany Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 164. Germany Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 165. France Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 166. France Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 167. France Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 168. Italy Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 169. Italy Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 170. Italy Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 171. United Kingdom Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 172. United Kingdom Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 173. United Kingdom Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 174. Netherlands Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 175. Netherlands Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 176. Netherlands Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 177. Rest of Europe Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 178. Rest of Europe Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 179. Rest of Europe Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 180. MEA Encephalitis Vaccine, by Country USD Million (2025-2030)
  • Table 181. MEA Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 182. MEA Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 183. MEA Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 184. Middle East Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 185. Middle East Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 186. Middle East Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 187. Africa Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 188. Africa Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 189. Africa Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 190. North America Encephalitis Vaccine, by Country USD Million (2025-2030)
  • Table 191. North America Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 192. North America Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 193. North America Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 194. United States Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 195. United States Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 196. United States Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 197. Canada Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 198. Canada Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 199. Canada Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 200. Mexico Encephalitis Vaccine, by Application USD Million (2025-2030)
  • Table 201. Mexico Encephalitis Vaccine, by End User USD Million (2025-2030)
  • Table 202. Mexico Encephalitis Vaccine, by Strain USD Million (2025-2030)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Encephalitis Vaccine: by Application USD Million (2018-2023)
  • Figure 5. Global Encephalitis Vaccine: by End User USD Million (2018-2023)
  • Figure 6. Global Encephalitis Vaccine: by Strain USD Million (2018-2023)
  • Figure 7. South America Encephalitis Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Encephalitis Vaccine Share (%), by Country
  • Figure 9. Europe Encephalitis Vaccine Share (%), by Country
  • Figure 10. MEA Encephalitis Vaccine Share (%), by Country
  • Figure 11. North America Encephalitis Vaccine Share (%), by Country
  • Figure 12. Global Encephalitis Vaccine share by Players 2023 (%)
  • Figure 13. Global Encephalitis Vaccine share by Players (Top 3) 2023(%)
  • Figure 14. Global Encephalitis Vaccine share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Liaoning Chengda (China) Revenue, Net Income and Gross profit
  • Figure 17. Liaoning Chengda (China) Revenue: by Geography 2023
  • Figure 18. Wuhan Institute of Biological (China) Revenue, Net Income and Gross profit
  • Figure 19. Wuhan Institute of Biological (China) Revenue: by Geography 2023
  • Figure 20. Valneva (France) Revenue, Net Income and Gross profit
  • Figure 21. Valneva (France) Revenue: by Geography 2023
  • Figure 22. Tiantan Biological Products (China) Revenue, Net Income and Gross profit
  • Figure 23. Tiantan Biological Products (China) Revenue: by Geography 2023
  • Figure 24. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 25. Sanofi Pasteur (France) Revenue: by Geography 2023
  • Figure 26. Chengdu Institute of Biological Products (China) Revenue, Net Income and Gross profit
  • Figure 27. Chengdu Institute of Biological Products (China) Revenue: by Geography 2023
  • Figure 28. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 30. Lanzhou Institute of Biological Products (China) Revenue, Net Income and Gross profit
  • Figure 31. Lanzhou Institute of Biological Products (China) Revenue: by Geography 2023
  • Figure 32. Zhejiang Tianyuan Bio-Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 33. Zhejiang Tianyuan Bio-Pharmaceutical (China) Revenue: by Geography 2023
  • Figure 34. Biken (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Biken (Japan) Revenue: by Geography 2023
  • Figure 36. Global Encephalitis Vaccine: by Application USD Million (2025-2030)
  • Figure 37. Global Encephalitis Vaccine: by End User USD Million (2025-2030)
  • Figure 38. Global Encephalitis Vaccine: by Strain USD Million (2025-2030)
  • Figure 39. South America Encephalitis Vaccine Share (%), by Country
  • Figure 40. Asia Pacific Encephalitis Vaccine Share (%), by Country
  • Figure 41. Europe Encephalitis Vaccine Share (%), by Country
  • Figure 42. MEA Encephalitis Vaccine Share (%), by Country
  • Figure 43. North America Encephalitis Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Liaoning Chengda (China)
  • Wuhan Institute of Biological (China)
  • Valneva (France)
  • Tiantan Biological Products (China)
  • Sanofi Pasteur (France)
  • Chengdu Institute of Biological Products (China)
  • GlaxoSmithKline (United Kingdom)
  • Lanzhou Institute of Biological Products (China)
  • Zhejiang Tianyuan Bio-Pharmaceutical (China)
  • Biken (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 243 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Encephalitis Vaccine Quantitative research analysis
Global (United States, European Union and China) Encephalitis Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Liaoning Chengda (China), Wuhan Institute of Biological (China), Valneva (France), Tiantan Biological Products (China), Sanofi Pasteur (France), Chengdu Institute of Biological Products (China), GlaxoSmithKline (United Kingdom), Lanzhou Institute of Biological Products (China), Zhejiang Tianyuan Bio-Pharmaceutical (China) and Biken (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Research and Development Activities" is seen as one of major influencing trends for Encephalitis Vaccine Market during projected period 2023-2030.
The Encephalitis Vaccine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global (United States, European Union and China) Encephalitis Vaccine Report?

Have a Query? Click Here

Other Related Reports

Medical Marijuana Comprehensive Study by Type (Buds, Oil, Tinctures), Application (Chronic Pain, Mental Disorders, Arthritis, Migraine, Cancer, Other), Marijuana Type (Medical Marijuana, Recreational...
$ 3500
Orphan Drugs Comprehensive Study by Drug Type (Biologics, Non-Biologics), Sale (Generics, Prescribed), Drugs (Revlimid, Rituxan, Opdivo, Others), Disease Type (Oncology, Gastrointestinal, Pulmonary, ...
$ 3750
Diptheria Vaccine Comprehensive Study by Type (Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quaracel), Disease Type (Diphtheria, Tetanus, Pertussis), Packaging Type (0.5 ML, 1 ML, 2 ML, Others), A...
$ 3450
Bio-pharma Comprehensive Study by Type (Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, G...
$ 3750
Polio Vaccines Comprehensive Study by Type (IPV (Inactivated Poliovirus Vaccine), OPV (Oral Polio Vaccine)), Application (Hospital, Clinics, Public Services, Others) Players and Region - Global Marke...
$ 3500
Impetigo Drug Comprehensive Study by Type (FMX-102, LTX-109, Mupirocin, Ozenoxacin, Others), Route of Administration (Topical, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail ...
$ 3500